ABBV
AbbVie Inc. Healthcare - Pharmaceuticals Investor Relations →
AbbVie Inc. (ABBV) closed at $210.39 as of 2026-05-15, trading 26.6% above its 200-week moving average of $166.22. The stock moved further from the line this week, up from 22.3% last week. The 14-week RSI sits at 44, indicating neutral momentum.
Trading volume is running at 0.8x of its 14-week average, which is in the normal range. The balance between buying and selling volume (0.94 ratio) is neutral — neither side is clearly dominating.
Over the past 649 weeks of data, ABBV has crossed below its 200-week moving average 2 times. On average, these episodes lasted 6 weeks. Historically, investors who bought ABBV at the start of these episodes saw an average one-year return of +60.1%.
With a market cap of $371.7 billion, ABBV is a large-cap stock. The company generates a free cash flow yield of 5.6%, which is healthy. The stock trades at -55.9x book value.
ABBV is a Dividend Aristocrat, having increased its dividend for 25 or more consecutive years. The current yield is 329.00%.
Over the past 12.5 years, a hypothetical investment of $100 in ABBV would have grown to $686, compared to $495 for the S&P 500. That represents an annualized return of 16.7% vs 13.7% for the index — confirming ABBV as a market-beating investment and the kind of quality company where buying during 200-week moving average touches has historically been rewarded.
Free cash flow has been declining at a -9.8% compound annual rate. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: ABBV vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After ABBV Crosses Below the Line?
Across 2 historical episodes, buying ABBV when it crossed below its 200-week moving average produced an average return of +51.5% after 12 months (median +55.0%), compared to +34.5% for the S&P 500 over the same periods. 100% of those episodes were profitable after one year. After 24 months, the average return was +116.0% vs +67.0% for the index.
Each line shows $100 invested at the moment ABBV crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Bean Score Experimental
The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. Between earnings dates, FCF is constant — so the score is purely a function of stock price. The levels below show at what prices ABBV would reach each dislocation threshold.
Dislocation Price Levels
Prices where ABBV's Bean Score would hit each σ threshold. Valid until next earnings report (last report: 2025-12-31).
| Level | σ | Price | Signal |
|---|---|---|---|
| Deep Value | +2σ | $200.13 | Unusually cheap — potential buy zone |
| Value | +1σ | $207.84 | Cheap vs. own history |
| Fair Value | +0σ | $216.16 | Historical mean behavior |
| Expensive | -1σ | $225.19 | Expensive vs. own history |
| Deep Expensive | -2σ | $234.99 | Unusually expensive — potential trim zone |
Signal Accuracy Collecting Data
The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"
Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are reference points for identifying potential swing trade opportunities, not buy/sell signals. FCF values update quarterly with earnings; between reports, all movement is price-driven.
Historical Touches
ABBV has crossed below its 200-week MA 2 times with an average 1-year return of +60.1% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Jul 2019 | Sep 2019 | 11 | 8.9% | +47.3% | +296.7% |
| Mar 2020 | Mar 2020 | 1 | 12.8% | +73.0% | +319.5% |
| Average | 6 | — | +60.1% | — |
Frequently Asked Questions
Is ABBV below its 200-week moving average?
No. AbbVie Inc. (ABBV) is currently 26.6% above its 200-week moving average of $166.22. It would need to fall to $166.22 to cross below the line.
What is ABBV's 200-week moving average price?
AbbVie Inc.'s 200-week moving average is $166.22 as of 2026-05-15. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when ABBV drops below its 200-week moving average?
ABBV has crossed below its 200-week moving average 2 times in our data. On average, buying at that moment produced a one-year return of +60.1%. These dips have historically been decent entry points. These episodes lasted 6 weeks on average.
Is ABBV a good value right now?
Here's what our data says about ABBV as of 2026-05-15: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 44. Free cash flow yield is 5.6%. Price-to-book is -55.9x. This is not a buy or sell recommendation — always do your own research.
How does ABBV compare to the S&P 500?
Over the past 12.5 years, $100 invested in ABBV would have grown to $686, compared to $495 for the S&P 500. That's 16.7% annualized vs 13.7% for the index. ABBV has outperformed the broader market over this period.
Does ABBV pay a dividend?
Yes. AbbVie Inc. currently pays a dividend yield of 329.00%. It is also a Dividend Aristocrat, meaning it has raised its dividend for 25 or more consecutive years.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-05-15